Tolerance of weekly metronomic paclitaxel and carboplatin as neoadjuvant chemotherapy in advanced ovarian cancer patients who are unlikely to tolerate 3 weekly paclitaxel and carboplatin

Objective: There are little data regarding safety and effectiveness of neoadjuvant chemotherapy (NACT) in patients who are considered unfit for receiving 3 weekly paclitaxel and carboplatin. The aim of this study was to examine the toxicity and response rates of weekly paclitaxel and carboplatin as...

وصف كامل

التفاصيل البيبلوغرافية

الحاوية / القاعدة:	South Asian Journal of Cancer
المؤلفون الرئيسيون:	S B Dessai, S Chakraborty, T. V. S. Babu, S Nayanar, A Bhattacharjee, J Jones, S Balasubramanian, Vijay M Patil
التنسيق:	مقال
اللغة:	الإنجليزية
منشور في:	Thieme Medical and Scientific Publishers Pvt. Ltd. 2016-01-01
الموضوعات:	Intolerable metronomic neoadjuvant chemotherapy poor nutritional status poor performance status
الوصول للمادة أونلاين:	http://journal.sajc.org/article.asp?issn=2278-330X;year=2016;volume=5;issue=2;spage=63;epage=66;aulast=Dessai